Table 3.

Univariate and multivariate analysis for relapse-free survival (RFS) and overall survival (OS) for patients with stage IV melanoma

Univariate Analysis-Stage IV
Covariate	RFS			OS
	HR	95%CI	P-value	HR	95%CI	P-value
Age	1.02	1.00–1.04	< 0.05	1.01	0.99–1.03	0.23
Sex	1.34	0.79–2.35	0.27	1.75	0.91–3.64	0.09
Breslow thickness	1.09	0.97–1.20	0.15	1.09	0.98–1.18	0.12
ALC (continuous)	0.54	0.34–0.85	< 0.008	0.68	0.37–1.23	0.20
ALC < 1.9 × 109/L	2.07	1.23–3.60	< 0.006	1.61	0.84–3.28	0.15
AMC (continuous)	3.50	0.87–12.4	0.08	0.84	0.14–4.19	0.84
AMC ≥ 0.6 × 109/L	1.54	0.92–2.54	0.09	0.93	0.48–1.74	0.84
Prior systemic therapy	1.23	0.75–2.01	0.41	1.05	0.56–1.93	0.87
Disease-free interval	0.99	0.99–1.00	0.26	1.00	0.99–1.01	0.97
No. metastatic sites (> 1)	0.99	0.48–1.87	0.99	0.58	0.20–1.34	0.22
Intervening regional disease	1.17	0.70–1.94	0.53	0.99	0.53–1.81	0.98
Adjuvant therapy	0.67	0.41–1.12	0.12	0.68	0.37–1.24	0.20
Multivariate Analysis-Stage IV
Covariate	RFS			OS
	HR	95%CI	P-value	HR	95%CI	P-value
Age	1.01	0.98–1.04	0.43	1.02	0.99–1.06	0.09
Breslow thickness	1.08	0.96–1.20	0.20	1.11	0.99–1.21	0.08
ALC < 1.9 × 109/L	2.22	1.07–4.88	< 0.03	1.05	0.42–2.82	0.91
AMC ≥ 0.6 × 109/L	1.58	0.79–3.10	0.19	0.93	0.39–2.09	0.86
Adjuvant therapy	1.09	0.57–2.15	0.79	0.99	0.49–2.03	0.99

Abbreviations: ALC, absolute lymphocyte count; AMC, absolute monocyte count.